When Should COVID Vaccines Get Full Approval? US FDA Squeezed By ‘Too Fast’ And ‘Too Slow’ Camps
Executive Summary
Some experts argue full FDA approval will help boost vaccination rates that are waning, but others want the agency to mandate studies in special populations and gather other data before making a final decision.
You may also be interested in...
Novavax Gains US FDA Advisory Committee Endorsement, But So Does Myocarditis Risk Statement
Vaccines and Related Biological Products Advisory Committee members agree another option should be made available, especially if Novavax's protein-based design could encourage those who refused the mRNA vaccines to be inoculated.
US FDA’s Top Two Vaccine Officials Announce Surprise Retirements
Departures of Marion Gruber and Philip Krause may stem from White House and CDC actions related to the COVID-19 vaccines.
US COVID-19 Vaccine Booster Plan Also Boosts Pressure On FDA
The plan’s White House announcement was described as a transparency move, but meeting its 20 September target start date requires both the FDA and ACIP to act quickly on boosters.